B-cell-specific signatures reveal novel immunophenotyping and therapeutic targets for hepatocellular carcinoma

Figure 8 Assessment of the immune microenvironment in different risk score groups. A: Box plot illustrates the stromal score across different risk score groups; B: Box plot displays the immune score across different risk score groups; C: Box plot showcases the estimate score across different risk score groups; D: Bubble plot demonstrates the correlation between risk score and immune cell infiltration within hepatocellular carcinoma samples; E: Box plot shows the abundance of immune cells across different risk score groups calculated based on the single-sample gene set enrichment analysis (ssGSEA) algorithm; F: Box plot exhibits the abundance of immune cells across different risk score groups calculated based on the cell-type identification by estimating relative subsets of RNA transcripts (CIBERSORT) algorithm; G: Heatmap displays the distribution and proportions of immune cells across different risk score groups calculated based on the CIBERSORT algorithm; H: Box plot demonstrates the immune functional status across different risk score groups calculated based on the ssGSEA algorithm; I: Association between The Cancer Genome Atlas immune subtypes and BRGs prognostic subtypes; J: Box plot showcases the expression of immune checkpoint genes across different risk score groups; K: Survival analysis depicts the immune therapy response and efficacy in different risk score groups of the IMvigor210 immune therapy cohort. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. LIHC: Liver hepatocellular carcinoma; CD: Cluster of differentiation; NK: Nature kill; DC: Dendritic cells; HLA: Human leukocyte antigen; TCGA: The cancer genome atlas.